MarketPulse

neuroscience

4 articles
BenzingaBenzinga··Na

Teva Bets $700M on Emalex to Bolster Neuroscience Portfolio With First-in-Class Tourette Drug

Teva acquires Emalex Biosciences for $700M upfront plus $200M in milestones for first-in-class Tourette syndrome therapy, closing by Q3 2026.
TEVAacquisitionNDA submission
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Beyond Weight Loss: Eli Lilly's Diversified Pipeline Offers More Growth Than Rivals

Eli Lilly's oncology and immunology portfolios rival its blockbuster weight-loss drugs, positioning the company better than Novo Nordisk for long-term growth.
LLYNVOCNTAgene therapyweight loss drugs
BenzingaBenzinga··Vandana Singh

Eli Lilly to Acquire Centessa for $6.3B, Bolstering Sleep Medicine Push

Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B upfront plus $1.5B in contingent payments, gaining sleep disorder pipeline including cleminorexton candidate.
LLYCNTAacquisitionneuroscience
GlobeNewswire Inc.GlobeNewswire Inc.··Bioxcel Therapeutics, Inc.

BioXcel Therapeutics Raises $8M via Direct Offering Amid Market Challenges

BioXcel Therapeutics raises $8M via direct offering of 4.5M shares at $1.739/share, with warrant modifications agreed, closing expected March 2026.
BTAIartificial intelligencewarrants